Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Gains from Investment Securities (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed Gains from Investment Securities for 2 consecutive years, with $900000.0 as the latest value for Q4 2025.

  • Quarterly Gains from Investment Securities rose 1600.0% to $900000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $840000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $12.5 million for FY2025, 28.39% up from the prior year.
  • Gains from Investment Securities for Q4 2025 was $900000.0 at Pyxis Oncology, up from $697237.0 in the prior quarter.
  • The five-year high for Gains from Investment Securities was $12.2 million in Q1 2025, with the low at -$60000.0 in Q4 2024.